Regentatlantic Capital LLC Exelixis, Inc. Transaction History

Regentatlantic Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$14.46 - $21.8 $191,363 - $288,501	-13,234 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$15.15 - $18.89 $29,163 - $36,363	-1,925 Reduced 12.7%	13,234 $233,000
Q3 2019 Oct 22, 2019	BUY	$17.68 - $22.65 $2,492 - $3,193	141 Added 0.94%	15,159 $268,000
Q2 2019 Jul 23, 2019	SELL	$18.93 - $24.75 $18,589 - $24,304	-982 Reduced 6.14%	15,018 $321,000
Q1 2019 May 03, 2019	BUY	$19.6 - $24.76 $39,200 - $49,520	2,000 Added 14.29%	16,000 $381,000
Q4 2018 Jan 30, 2019	SELL	$13.65 - $21.8 $682 - $1,090	-50 Reduced 0.36%	14,000 $275,000
Q3 2018 Oct 30, 2018	BUY	$15.87 - $22.4 $222,973 - $314,720	14,050 New	14,050 $249,000

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Regentatlantic Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Regentatlantic Capital LLC with notifications on news.